Table 1.

Registered clinical trials using MSCs for COVID-19.

ID	Sample size	Intervention	Comparison group	Primary outcome
NCT04339660	30	1∗106/kg body weight UC-MSCs	Placebo (saline)	•Improvement and recovery time of inflammatory and immune factors •Blood oxygen saturation
NCT04252118	20	3 times 3∗107 MSCs	Conventional treatment	•Size of lesion area by CT •Side effects in MSCs treated group
NCT04361942	24	1∗106/kg body weight MSCs	Placebo	•Withdrawn of mechanical ventilation •Mortality rate
NCT04362189	110	4 times 1 ∗ 108ADSCs + HC + AZ	Placebo (saline) + HC + AZ	•Mortality rate •Change in need of mechanical ventilation
NCT04336254	20	3 times 3∗107 DPSCs	Placebo	•Time for clinical improvement
NCT04348435	100	5 times 0.5/1/2∗108 ADSCs	Placebo	•Incidence of hospitalization •Incidence of symptoms
NCT04313322	5	3 times 1∗106/kg body weight WJ-MSCs	–	•Improvement in clinical symptoms •Chest radiographs •Virus shedding (RT-PCR results)
NCT04315987	66	3 times 2∗107 NestCell®	–	•Change in clinical outcome
NCT04273646	48	4 times 0.5∗106/kg body weight UC-MSCs	Placebo	•Pneumonia severity index •Oxygenation index
NCT04346368	20	1∗106/kg body weight BMSCs	Placebo	•Oxygenation index •Side effects of BMSCs
NCT04288102	90	3 times 4∗107 MSCs	Placebo	•Size of lesion area •Severity of pulmonary fibrosis
NCT04349631	56	ADSCs	–	•Incidence of hospitalization •Incidence of symptoms
NCT04352803	20	5∗105/kg body weight ADSCs	Untreated	•Incidence of adverse events in treated group •Mechanical ventilation needs •Length of hospital stay •Mortality rate
NCT04355728	24	2 times 1∗108 UC-MSCs	Standard care therapy	•Incidence of adverse events
NCT04366323	26	2 times 8∗107 ADSCs	No intervention	•Adverse event rate •Survival rate
NCT04345601	30	1∗108 BMSCs	–	•Incidence of adverse events •Improvement in oxygen saturation
NCT04366063	60	2 times 1∗108 MSCs 2 times 1∗108 MSCs + 2 times EVs	Conventional therapy	•Adverse events assessment •Blood oxygen saturation
NCT04302519	24	3 times 1∗106/kg body weight DPSCs	–	•Disappearance of ground glass opacity in lungs
NCT04331613	9	3/5/10∗106hESCs derived M cells	–	•Assessment of adverse events •Lung imaging examinations
NCT04366271	106	UC-MSCs	Standard care	•Mortality rate
NCT04367077	400	MultiStem ® (BMSCs)	Placebo	•Ventilator free days •Adverse events assessment
NCT04333368	60	3 times 1∗106/kg body weight UC-MSCs	Placebo	•Respiratory efficacy
NCT04348461	100	2 times 1.5∗106/kg body weight ADSCs	Conventional treatment	•Survival rate assessment •Adverse events assessment
NCT04341610	40	1∗108 ADSCs	Placebo	•Changes in clinical critical treatment index
NCT04299152	20	Mononuclear cells treated with UC-MSCs	Conventional treatment	•Number of patients who will be unable to complete SCE therapy
NCT04416139	10	1∗106 MSCs/kg body weight	No intervention	•Functional respiratory changes •Clinical cardiac and respiratory changes •Changes in body temperature
NCT04452097	9	0.5–1.5 ∗ 106/body weight UC-MSCs	–	•Incidence of infusion related adverse events •Incidence of treatment related adverse events
NCT04437823	20	3 times 5 ∗ 105/body weight UC-MSCs	Standard care	•Safety of MSCs infusion •Chest CT scan
NCT04429763	30	1 ∗ 106/body weight UC-MSCs	Placebo	•Clinical deterioration or death
NCT04269525	10	4 times 3.3∗107 UC-MSCs	–	•Oxygenation index
NCT04444271	20	2 times 2∗106/kg body weight BMSCs	Placebo	•Clinical improvement in terms of oxygen support •Time of negative COVID-19 PCR result •Radiological improvement •Days required to discharge from hospital
NCT04428801	200	3 times 2∗ 108 ADSCs	Placebo	•Safety of ADSCs infusion •COVID-19 incidence rates
NCT04276987	30	5 times 2∗108 ADSCs-EVs	–	•Adverse events assessment •Clinical improvement